# Ipsen Boosts Sales Growth and Upgrades 2026 Guidance

> Ipsen reports 24.6% year-to-date sales growth and raises full-year 2026 financial targets.
- Title: Ipsen Boosts Sales Growth and Upgrades 2026 Guidance
- Summary: Ipsen reports 24.6% year-to-date sales growth and raises full-year 2026 financial targets. Ipsen achieved 24.6% year-to-date sales growth and upgraded its…
- Keywords: ipsen, sales growth, full-year guidance, core portfolio, somatuline, dysport, iqirvo, navtemadlin, potravitug, money, business, Boosts
- Source: Financialpost — https://financialpost.com/globe-newswire/ipsen-delivers-outstanding-sales-growth-in-the-first-nine-months-of-2026-and-further-upgrades-its-full-year-guidance
- Read time: 1 min
- Topics: ipsen, sales growth, full-year guidance, core portfolio, somatuline, dysport, iqirvo, navtemadlin, potravitug, money, business
## Ipsen Sales Growth
Ipsen reported 24.6% year-to-date sales growth at CER, up from 23.0% in 2025.

> Year-to-date total sales growth of 24.6% at CER, or 23.0% as reported
## Upgraded 2026 Guidance
Ipsen raised full-year 2026 sales growth guidance to 23.0% at CER and core operating margin to 39.0%.

> Total sales growth around 23.0% at CER (prior guidance: greater than 20.0% at CER); core operating margin around 39.0% of total sales (prior guidance: greater than 37.0%)
## Pipeline Strengthens
Ipsen's late-stage pipeline includes oncology, rare disease and neuroscience assets with blockbuster potential.

> Multiple late-stage pipeline assets with blockbuster potential in Oncology, Rare Disease and Neuroscience
## CEO Statement
CEO David Loew attributes growth to core portfolio strength and Somatuline sales expansion.

> Our outstanding performance in the first nine months of 2026 is driven by the strength of our core portfolio and continued growth of Somatuline
## Key Pipeline Assets
Ipsen's pipeline includes Dysport for migraine, Iqirvo for primary biliary cholangitis and navtemadlin for myelofibrosis.

> We have the potential to address substantial unmet needs and expand our reach to new patient populations through Dysport in episodic and chronic migraine and, through Iqirvo with a potential label update in primary biliary cholangitis
## Acquisitions Boost Pipeline
Ipsen acquired Memo Therapeutics and Kartos Therapeutics to add potravitug and navtemadlin to its pipeline.

> Ipsen completed the acquisitions of Memo Therapeutics and Kartos Therapeutics, adding potravitug, a late-stage anti-BK polyomavirus monoclonal antibody, and navtemadlin, a Phase III MDM2 inhibitor for myelofibrosis
## Key takeaway

Ipsen achieved 24.6% year-to-date sales growth and upgraded its 2026 sales and margin guidance to 23.0% and 39.0%.